Joseph Polli Named AAPS President-Elect

Published on: 

Pharmaceutical scientist association announces upcoming term’s board of directors.

Joseph W. Polli from GlaxoSmithKline has been elected to serve as president-elect of the American Association of Pharmaceutical Scientists (AAPS) and will begin a three-year term on the AAPS Board of Directors (as president-elect, president, and immediate past president) in November 2018 at the AAPS PharmSci 360 meeting in Washington, DC.

“My focus as president-elect will be to ensure that decisions from the AAPS Board of Directors drives member value, delivers the ongoing transformation of the association, and maintains the current fiscal stewardship, with a vision that AAPS will be prepared to serve and advance the capacity of the next generation of pharmaceutical scientists. It would be an honor to serve as the 2018–2019 president-elect,” Polli noted in his election bulletin.

AAPS also announced that Douglas H. Sweet, Virginia Commonwealth University, was elected as a member-at-large and Mark J. Rose, CHDI Management, Inc. was elected to serve as treasurer.


Other members on the 2019 AAPS Board of Directors are Members-at-Large Reina Bendayan, University of Toronto; Allen C. Templeton, Merck & Co., Inc; Annette Bak, AstraZeneca; Bernd W. Meibohm, the University of Tennessee Health Science Center; and President Dale E. Wurster and Past President Christopher R. McCurdy.

Source: AAPS